ENYO Pharma Announces a €39 Million Series C Financing and FDA Clearance to Advance Vonafexor in a Phase 2 Clinical Trial for Patients With Alport Syndrome
The Company will initiate a Phase 2 clinical study of Vonafexor in Alport Syndrome - called “ALPESTRIA-1” - in the first half of 2024. Series C proceeds will fund the Phase 2 study, as well as operations and further R&D through the first half of 2026. ENYO Pha





